Citations

Clear

3485 citation(s) found for "Sy, Sarah".

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).
Gelman, Rebecca , Melisko, Michelle , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Farooq, Sarah , Cropp, Anne B., Cotter, Christine M., Liu, Minetta C. , Krop, Ian E. , Nangia, Julie R. , Freedman, Rachel A. , Anders, Carey K. , Moy, Beverly , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 1005-1005

10.1200/jco.2017.35.15_suppl.1005 Get It

1005 Background: Evidence-based treatments (tx) for metastatic, HER2+ BCBM are limited. We previously found a central nervous system (CNS) objective response rate (ORR) of 8% (95% CI 2-22%) for the irreversible, EGFR/HER2-targeted kinase inhibitor, neratinib. To enhance CNS activity, we evaluated the combination of neratinib + capecitabine in a subsequent cohort, and report results here. Methods: Pts with measurable BCBM (≥ 1 cm in longest dimension) and no prior lapatinib or capecitabine were eligible. All but 3 had CNS progression after local CNS tx. During 21 day cycles, pts received capecitabine 750 mg/m2 twice daily x 14 days followed by 7 days off + neratinib 240 mg orally once daily. Loperamide prophylaxis (16 mg total daily) was recommended during cycle 1. Brain MRI and non-CNS imaging were repeated every 2 cycles until 18 wks, then every 3 cycles. The primary endpoint was composite CNS ORR, requiring all of the following: ≥50% reduction in volumetric sum of target CNS lesions (central review, VORR), no progression of non-target or non-CNS lesions, no new lesions, no escalating steroids, and no progressive neurologic signs/symptoms. We used a two-stage design with hypotheses ORR 15% and 35% (error rates 5% and 20%), responses in ≥5/19 pts to enter 2ndstage; responses in ≥9/35 [26%] pts to be promising. Results: 39 pts enrolled between 4/2014-11/2016 (2 withdrew before tx, 37 analyzed); median age 51, median prior metastatic lines 2 (range 0-6), 65% had prior WBRT. As of 11/15/16, 23 (62%) patients are alive and 7 remain on protocol tx; median number of cycles initiated = 5 (range 1-26). 18 women (49%) had a VORR (95% CI 32-66%, neurologic exams not yet available on all pts). Overall 12-month survival is 63% (95% CI 43%-77%); 4/7 pts still on protocol therapy have not yet reached 6 cycles. No pts had grade 4 toxicity; 18 (49%) had grade 3 toxicity, with diarrhea most common (32%), and 6 pts discontinued tx for toxicity. Conclusions: The combination of neratinib and capecitabine is active for BCBM with VORR in nearly half of pts, supporting further development of the regimen for BCBM. Updated results will be presented at the meeting. Clinical trial information: NCT01494662.
Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.
Soyano, Aixa , Serie, Daniel, Mashadi-Hossein, Afshin , Warren, Sarah , Colón‐Otero, Gerardo , Knutson, Keith L. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Chumsri, Saranya , Soyano, Aixa , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 530-530

10.1200/jco.2017.35.15_suppl.530 Get It

530 Background: Therapeutic efficacy of H involves activation of the immune system.Age-dependent progressive deterioration of the immune response is referred as immunosenescence. In HER2+ breast cancer, the effects of aging and the ability of H to activate endogenous anti-tumor immunity is unknown. A previous report from HERA trial showed no significant increase in risk of early recurrence with age (≤ or > 40). We evaluated the long-term outcome of HER2+ patients (pt) related to age and immune landscape. Methods: 1,392 pt from N9831 trial were evaluated. Stromal tumor infiltrating lymphocytes (sTIL) were evaluated in H&E slides. Lymphocyte predominant breast cancer (LPBC) was defined as sTIL ≥ 50%. Molecular TIL (mTIL) and immune subset signatures were evaluated using NanoString research CodeSets. Cox proportional hazard ratio (HR) was used for analysis. Results: There were 1,111 (79.8%) pt > 40 years old (yo) and 281 (20.2%) pt ≤ 40 yo. Younger age was significantly associated with hormone receptor positivity (p 0.00011) and luminal B subtype (p 0.011). With a median follow up of 10.6 years, there was no significant difference in long-term outcome among pt ≤ 40 vs. > 40 yo who received H (HR = 0.88 (0.62-1.24), p = 0.45). Similar findings were observed when age was dichotomized at 50 and 60 yo. While there was no association between sTIL and age, a small but significant increase in mTIL CD45 expression with age (p 0.003) was observed. Similar small increases in cytotoxic cell (p 0.007) and T cell (p 0.015) immune scores were also observed with increasing age. Among pt who received chemotherapy alone, pt > 40 yo with LPBC (n 55) had excellent outcome with 92.4% recurrence free survival (RFS) at 10 years. However, there was no significant difference in RFS among pt ≤ 40 yo with or without LPBC. Conclusions: Among pt treated with H, there was no significant difference in outcome related to age. In contrast to a decline expected from immunosenescence, we observed small but significant increases in mTIL signatures for total lymphocytes, cytotoxic, and T cell subsets. Among patients who received chemotherapy alone, our data suggested that pt > 40 yo with LPBC had excellent prognosis, compared to pt > 40 yo without LPBC.
Inhibition of pancreatic cancer by targeting the epigenetic EZH2 complex.
Lomberk, Gwen , Missfeldt, Mckenna, Salmonson, Ann, Kossak, Sarah, Buttar, Navtej , Lomberk, Gwen L , Mathison, Angela , Urrutia, Raúl

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15736-e15736

10.1200/jco.2016.34.15_suppl.e15736 Get It

Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
Shih, Kent C. , Patel, Manish R. , Butowski, Nicholas , Kizilbash, Sani H. , Bacha, Jeffrey , Brown, Dennis , Steinø, Anne, Schwartz, Richard S. , Kanekal, Sarath, Lopez, Lorena, Burris, Howard A. , Kizilbash, Sani H , Falchook, Gerald Steven

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2063-2063

10.1200/jco.2016.34.15_suppl.2063 Get It

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.
Chumsri, Saranya , Sperinde, Jeff, Liu, Heshan , Moreno‐Aspitia, Alvaro , McLaughlin, Sarah A. , Winslow, John , Petropoulos, Christos J. , Chenna, Ahmed , Bates, Michael, Weidler, Jodi, Lie, Yolanda, Huang, Weidong , Perez, Edith A. , Gligorov, Joseph , Spano, Jean‐Philippe

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 603-603

10.1200/jco.2016.34.15_suppl.603 Get It

Temperature and humidity affect the incidence of hand, foot, and mouth disease: a systematic review of the literature – a report from the International Society of Dermatology Climate Change Committee
Coates, Sarah J. , Davis, Mark D.P. , Andersen, Louise K.

Mayo Clinic

International Journal of Dermatology | September 6, 2018 | Volume: 58 | Issue: 4 | Pages: 388-399

10.1111/ijd.14188 | PMID 30187452 Get It

AbstractHand, foot, and mouth disease (HFMD) is an enterovirus‐mediated condition that predominantly affects children under 5 years of age. The tendency for outbreaks to peak in warmer summer months suggests a relationship between HFMD and weather patterns. We reviewed the English‐language literature for articles describing a relationship between meteorological variables and HFMD. Seventy‐two studies meeting criteria were identified. A positive, statistically significant relationship was identified between HFMD cases and both temperature (61 of 67 studies, or 91.0%, reported a positive relationship) [CI 81.8–95.8%,P = 0.0001] and relative humidity (41 of 54 studies, or 75.9%) [CI 63.1–85.4%,P = 0.0001]. No significant relationship was identified between HFMD and precipitation, wind speed, and/or sunshine. Most countries reported a single peak of disease each year (most commonly early Summer), but subtropical and tropical climate zones were significantly more likely to experience a bimodal distribution of cases throughout the year (two peaks a year; most commonly late spring/early summer, with a smaller peak in autumn). The rising global incidence of HFMD, particularly in Pacific Asia, may be related to climate change. Weather forecasting might be used effectively in the future to indicate the risk of HFMD outbreaks and the need for targeted public health interventions.
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell, Robert F. , Bishop, Michael R. , Larson, Sarah , Borrello, Ivan , Kumar, Shaji , Rossi, John M. , Thomrongsith, Lisa, Xue, Allen , Roberts, Zachary , Locke, Frederick L. , Bishop, Michael Russell , Orlowski, Robert Z. , Giralt, Sergio , Nooka, Ajay K. , Raje, Noopur

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS3103-TPS3103

10.1200/jco.2018.36.15_suppl.tps3103 Get It

ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.
Dubuc, Adrian M. , Gaffey, Sarah, Gedulig, Jack E., Ramkissoon, Shakti, Groot, John Frederick De, Welch, Mary , Schiff, David , Ahluwalia, Manmeet S. , Colman, Howard , Wen, Patrick Y. , Ahluwalia, Manmeet S , Touat, Mehdi , Meredith, David M. , Galanis, Evanthia , Nabors, Burt , Arrillaga, Isabel, Chiocca, E Antonio , Santagata, Sandro , Colman, Howard , Drappatz, Jan , Alexander, Brian M. , Wen, Patrick Yung , Ligon, Keith L

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2003-2003

10.1200/jco.2018.36.15_suppl.2003 Get It

Incidence of pathogenic variants in individuals with a personal or family history of pancreatic cancer.
Macklin, Sarah , Hines, Stephanie L., Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1589-1589

10.1200/jco.2018.36.15_suppl.1589 Get It

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.
Chumsri, Saranya , Serie, Daniel, Kachergus, Jennifer M., Warren, Sarah , Colón‐Otero, Gerardo , Hilbers, Florentine , Dooren, Veerle Van, Holmes, Eileen , Werner, Olena, Huober, Jens , Baselga, José , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Mashadi-Hossein, Afshin , Partridge, Ann H. , Carey, Lisa A. , Cosimo, Serena Di , Sotiriou, Christos P. , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 577-577

10.1200/jco.2018.36.15_suppl.577 Get It